NCT00391638 - Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2011

Study Completion Date

October 31, 2012

Conditions

Hepatitis BHIV Infections

Interventions

DRUG

TRUVADA (EMTRICITABINE + TENOFOVIR DF)

Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day

BIOLOGICAL

PEGASYS 180μg (Interféron pégylé alpha -2a)

Pegasys ® injection 180μg Dosage: A subcutaneous injection per week

Trial Locations (2)

Service des Maladies Infectieuses CHU, Dijon

Service d'Hépato-Gastroentérologie Hopital Hôtel-Dieu, Lyon